Herring WL, Gould IG, Wittrup-Jensen V, Ertle J, Kuti E, Wolowacz S. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes. J Comp Eff Res. 2022 Dec 1;11(18):1349-63. doi: 10.2217/cer-2021-0194
Watson V, McCartan N, Krucien N, Abu V, Ikenwilo D, Emberton M, Ahmed HU. Evaluating the trade-offs men with localized prostate cancer make between the risks and benefits of treatments: the COMPARE study. J Urol. 2020 Aug;204(2):273-80. doi: 10.1097/JU.0000000000000754
Joshi K, Muser E, Xu Y, Schwab P, Datar M, Suehs B. Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population. J Comp Eff Res. 2018 Aug;7(8):723-35. doi: 10.2217/cer-2018-0003
Meyers J, Gajria K, Candrilli SD, Fridman M, Sikirica V. The impact of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorder. J Comp Eff Res. 2017 Mar;6(2):109-25. doi: 10.2217/cer-2016-0039
Rosen RC, Wincze J, Mollen MD, Gondek K, McLeod LD, Fisher WA. Responsiveness and minimum important differences for the erection quality scale. J Urol. 2007 Nov 1;178(5):2076-81.
Watson V, Ryan M, Brown CT, Barnett G, Ellis BW, Emberton M. Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2004 Dec;172(6 Pt 1):2321-5. doi: 10.1097/01.ju.0000140957.31325.7f
Yang BK, Young MD, Calingaert B, Albala DM, Vieweg J, Murphy BC, Dahm P. Prospective and longitudinal patient self-assessment of health-related quality of life following radical perineal prostatectomy. J Urol. 2004 Jul 1;172(1):264-8.
Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol. 2000 Feb 1;163(2):460-3.